The quarterly performance reveals fundamental challenges in the company's investment-driven business model, with negative net sales of ₹7.44 crores marking a dramatic reversal from the previous quarter's positive ₹3.72 crores. This represents a staggering sequential decline of 300.00%, underscoring extreme volatility in the company's revenue generation capability. The profit after tax margin collapsed to 98.79%, whilst operating profit before depreciation, interest and tax (PBDIT) plunged to negative ₹8.73 crores.
The company's erratic quarterly performance reflects the inherent risks of a business model entirely dependent on stock market movements and investment income. Unlike traditional NBFCs engaged in lending activities, Crescentis Capital generates revenue primarily through dividends, investment income, and capital gains from its equity portfolio. This structure exposes the company to significant volatility, as evidenced by the wild swings in quarterly results over the past two years.
| Quarter | Net Sales (₹ Cr) | QoQ Change | Net Profit (₹ Cr) | QoQ Change | PAT Margin % |
|---|---|---|---|---|---|
| Mar'26 | -7.44 | ▼ 300.00% | -7.35 | ▼ 717.65% | 98.79% |
| Dec'25 | 3.72 | ▲ 1330.77% | 1.19 | ▲ 347.92% | 31.99% |
| Sep'25 | 0.26 | ▼ 94.75% | -0.48 | ▼ 114.33% | -184.62% |
| Jun'25 | 4.95 | ▼ 232.71% | 3.35 | ▲ 188.62% | 67.68% |
| Mar'25 | -3.73 | ▼ 12.65% | -3.78 | ▼ 11.89% | 101.34% |
| Dec'24 | -4.27 | ▼ 14333.33% | -4.29 | ▼ 725.00% | 100.47% |
| Sep'24 | 0.03 | — | -0.52 | — | -1733.33% |
Financial Performance: Alarming Deterioration in Core Metrics
The March 2026 quarter witnessed a complete breakdown in financial performance across all key parameters. Net sales turned sharply negative at ₹7.44 crores, reversing from the positive ₹3.72 crores recorded in December 2025. This 300.00% sequential decline suggests significant mark-to-market losses on the company's investment portfolio, likely driven by adverse market conditions during the quarter.
Operating profit before depreciation, interest and tax (PBDIT) excluding other income plummeted to negative ₹8.79 crores, representing the lowest level in the company's recent history. The operating margin excluding other income stood at 118.15%, a meaningless metric given the negative revenue base. Employee costs remained relatively stable at ₹0.70 crores, but in the context of negative revenues, even modest fixed costs become burdensome.
The profit before tax deteriorated to negative ₹8.87 crores from negative ₹4.50 crores in the year-ago quarter, marking a 97.11% year-on-year decline. Tax credits of ₹1.52 crores provided marginal relief, resulting in a net loss of ₹7.35 crores. The effective tax rate of 17.14% appears inconsistent with the loss-making status, raising questions about deferred tax adjustments and carry-forward losses.
Operational Challenges: Investment Model Under Severe Stress
The company's return on equity (ROE) tells a tale of two periods. Whilst the average ROE over the past five years stands at a respectable 21.59%, the latest ROE has collapsed to just 0.34%, highlighting the severe deterioration in capital efficiency. This dramatic compression reflects the cumulative impact of recent quarterly losses eroding shareholder value. Higher ROE typically indicates better capital efficiency and profitability, but Crescentis Capital's current ROE of 0.34% signals virtually no returns being generated on equity capital.
The return on capital employed (ROCE) paints an even grimmer picture at negative 11.54%, indicating that the company is destroying value rather than creating it. This metric, which measures how efficiently capital is being deployed to generate profits, has turned deeply negative as operating losses mount. For a company in the investment business, negative ROCE is particularly concerning as it suggests fundamental challenges in portfolio management and asset allocation.
The balance sheet reveals a company with minimal leverage, carrying zero long-term debt across all reported periods. Shareholder funds stood at ₹14.20 crores as of March 2019, with reserves and surplus of ₹4.19 crores supplementing the ₹10.01 crores share capital. Current assets of ₹11.95 crores provide some liquidity cushion, though the deteriorating profitability raises questions about asset quality and realisable values.
Critical Concern: Structural Profitability Issues
The company's investment-driven business model has failed to generate consistent profits, with four out of the last seven quarters reporting net losses. The extreme volatility in quarterly results—swinging from profits to losses and back—indicates either poor risk management, concentrated portfolio positions, or a fundamental mismatch between the business model and market conditions. The negative ROCE of 11.54% and latest ROE of just 0.34% suggest the company is systematically destroying shareholder value rather than creating it.
Valuation Analysis: Extreme Multiples Disconnect from Fundamentals
Crescentis Capital trades at a price-to-earnings ratio of 735 times trailing twelve-month earnings, an astronomical valuation that appears completely disconnected from the company's operational reality. To put this in perspective, the broader NBFC industry trades at an average P/E of 23 times, making Crescentis Capital's valuation premium utterly unjustifiable given its loss-making status and deteriorating financial trends.
The price-to-book value ratio of 2.53 times suggests the market is valuing the company at more than double its net asset value of ₹24.58 per share. Whilst this premium might be warranted for high-growth, high-return businesses, it appears excessive for a company generating negligible returns on equity and posting consistent losses. The enterprise value-to-EBITDA multiple of 132.97 times further underscores the valuation disconnect.
The company's valuation grade has oscillated between "Risky" and "Very Expensive" over the past several months, with the most recent assessment categorising it as "Risky." This classification appears generous given the fundamental challenges. The 52-week trading range of ₹81.05 to ₹172.03 shows significant price volatility, with the current price of ₹121.30 sitting 29.49% below the 52-week high and 49.66% above the 52-week low.
Peer Comparison: Underperformance Across Key Metrics
When compared to peers in the NBFC sector, Crescentis Capital's valuation metrics appear particularly stretched. Whilst the company does demonstrate a higher average ROE of 21.59% compared to most peers, this historical strength has evaporated in recent quarters, with the latest ROE dropping to just 0.34%. The company maintains zero debt-to-equity ratio, which is a positive differentiator, but this conservative capital structure has not translated into superior returns.
| Company | P/E (TTM) | P/BV | ROE % | Debt/Equity | Div Yield |
|---|---|---|---|---|---|
| Crescentis Capital | 735.23 | 2.53 | 21.59 | 0.00 | NA |
| Team India Guarantee | 111.95 | 4.84 | 5.90 | 0.00 | NA |
| Shalibhadra Finance | 12.00 | 1.43 | 10.89 | 0.25 | 0.53% |
| Emerald Finance | 13.57 | 2.06 | 9.81 | 0.18 | NA |
| Capital Trade Links | 536.40 | 3.00 | 2.56 | 1.78 | NA |
The peer comparison reveals that Crescentis Capital trades at the highest P/E multiple in the group at 735.23 times, significantly above even Capital Trade Links' elevated 536.40 times. More fundamentally sound peers like Shalibhadra Finance and Emerald Finance trade at far more reasonable multiples of 12.00 times and 13.57 times respectively, whilst also maintaining positive profitability and paying dividends. The company's P/BV ratio of 2.53 times sits in the middle of the peer group, but appears unjustified given the deteriorating fundamentals.
Shareholding Pattern: Stable Promoter Base Provides Limited Comfort
The shareholding structure reveals strong promoter commitment, with Dr. Bhaskara Rao Bollineni and Mr. Ruthvik Reddy Bhavanam collectively holding 74.98% of the company's equity as of March 2026. This stake has remained unchanged for the past four quarters, following a 5.62 percentage point increase in July 2025. The stable promoter holding provides some governance comfort, though it also means limited free float and potential liquidity constraints for investors.
| Quarter | Promoter % | QoQ Change | FII % | MF % | Public % |
|---|---|---|---|---|---|
| Mar'26 | 74.98% | 0.00% | 0.00% | 0.00% | 25.02% |
| Dec'25 | 74.98% | 0.00% | 0.00% | 0.00% | 25.02% |
| Sep'25 | 74.98% | 0.00% | 0.00% | 0.00% | 25.02% |
| Jul'25 | 74.98% | +5.62% | 0.00% | 0.00% | 25.02% |
| Jun'25 | 69.36% | — | 0.00% | 0.00% | 30.64% |
Notably, the company has zero institutional participation, with no holdings from foreign institutional investors, mutual funds, or insurance companies. This complete absence of institutional interest is a significant red flag, suggesting professional investors have avoided the stock due to concerns about business model viability, governance, liquidity, or fundamental performance. The lack of institutional validation makes the elevated valuation multiples even more difficult to justify.
Stock Performance: Severe Long-Term Underperformance Despite Recent Resilience
The stock's performance presents a mixed picture across different timeframes. Over the past year, Crescentis Capital has declined 2.96%, outperforming the Sensex's 8.40% fall by generating a positive alpha of 5.44 percentage points. Short-term performance has been relatively stable, with the stock posting gains of 0.25% over one day, 0.66% over one week, and declining 2.18% over one month—all showing better resilience than the broader market.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Day | +0.25% | -1.44% | +1.69% |
| 1 Week | +0.66% | -0.85% | +1.51% |
| 1 Month | -2.18% | -3.51% | +1.33% |
| 3 Month | -2.45% | -8.01% | +5.56% |
| 6 Month | +8.59% | -12.75% | +21.34% |
| 1 Year | -2.96% | -8.40% | +5.44% |
| 2 Years | -10.87% | +0.37% | -11.24% |
| 3 Years | -44.00% | +18.98% | -62.98% |
| 5 Years | +597.13% | +45.41% | +551.72% |
However, the longer-term picture reveals severe wealth destruction. Over three years, the stock has plummeted 44.00% whilst the Sensex gained 18.98%, resulting in a devastating negative alpha of 62.98 percentage points. The two-year performance shows a decline of 10.87% against the Sensex's marginal 0.37% gain. These extended periods of underperformance align with the deteriorating fundamental performance and raise serious questions about the sustainability of the business model.
The stock's beta of 1.50 indicates high volatility, with movements 50% more pronounced than the broader market. With an annualised volatility of 64.37%, the stock falls into the "high risk, medium return" category—a particularly unfavourable risk-reward profile. The negative Sharpe ratio confirms that the stock has failed to compensate investors adequately for the elevated risk undertaken.
Investment Thesis: Multiple Red Flags Overwhelm Limited Positives
The investment case for Crescentis Capital is severely compromised by fundamental structural issues. The company's proprietary score of 50 out of 100 places it in "HOLD" territory, though even this appears generous given the deteriorating trends. The financial trend has been downgraded to "Negative" as of March 2026, reflecting the sharp quarterly losses and operational challenges. Quality assessment categorises the company as "Below Average," whilst valuation remains "Very Expensive" despite recent price corrections.
Key Strengths & Risk Factors
Key Strengths ✓
- Strong Historical ROE: Five-year average ROE of 21.59% demonstrates past capital efficiency, though this has evaporated in recent quarters
- Zero Debt: Conservative balance sheet with no long-term borrowings provides financial flexibility and eliminates refinancing risk
- Stable Promoter Holding: 74.98% promoter stake signals alignment with minority shareholders and commitment to the business
- Recent Price Resilience: Six-month return of 8.59% and positive alpha versus Sensex show some investor support despite fundamental challenges
- Adequate Liquidity: Current assets of ₹11.95 crores provide working capital cushion for near-term operations
Key Concerns ⚠
- Consistent Losses: Four out of last seven quarters loss-making, with Q4 FY26 loss of ₹7.35 crores marking severe deterioration
- Negative ROCE: Return on capital employed at negative 11.54% indicates systematic value destruction rather than creation
- Collapsed ROE: Latest ROE of just 0.34% represents a catastrophic decline from the 21.59% five-year average
- Extreme Valuation: P/E of 735 times and EV/EBITDA of 132.97 times completely disconnected from loss-making fundamentals
- Zero Institutional Interest: Complete absence of FII, mutual fund, and insurance holdings raises serious governance and viability concerns
- Business Model Risk: Pure-play investment company exposed to market volatility with no diversified revenue streams
- Long-Term Underperformance: Three-year return of negative 44.00% versus Sensex gain of 18.98% shows sustained wealth destruction
Outlook: What to Watch
Positive Catalysts
- Return to profitability in Q1 FY27 would signal stabilisation of investment portfolio
- Improved ROE and ROCE metrics demonstrating better capital allocation
- Entry of institutional investors providing validation and liquidity
- Diversification of revenue streams beyond pure equity investments
Red Flags to Monitor
- Continuation of quarterly losses beyond Q1 FY27 would confirm structural issues
- Further deterioration in ROE and ROCE metrics
- Any reduction in promoter holding given lack of institutional interest
- Declining book value per share indicating erosion of net worth
- Inability to generate positive cash flows from operations
The Verdict: Avoid—Fundamental Model Breakdown Outweighs Any Positives
Score: 50/100
For Fresh Investors: Avoid initiation entirely. The combination of consistent quarterly losses, negative ROCE, collapsed ROE, extreme valuation multiples, and complete absence of institutional interest makes this an unsuitable investment. The business model appears fundamentally challenged, with no clear path to sustainable profitability.
For Existing Holders: Consider exiting positions at current levels. Whilst the stock has shown some recent price resilience, the underlying fundamentals continue to deteriorate sharply. The Q4 FY26 loss of ₹7.35 crores and negative ROCE of 11.54% signal systematic value destruction. With zero institutional validation and trading at a P/E of 735 times despite losses, the risk-reward profile is highly unfavourable.
Fair Value Estimate: ₹85.00 (29.93% downside from current price of ₹121.30). This estimate applies a conservative 3.5 times price-to-book multiple to the book value of ₹24.58, reflecting the below-average quality, negative financial trend, and structural profitability challenges.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
